Giredestrant is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include RO-7197597 and GDC-9545. Its PubChem CID is 121410806.
Giredestrant
| CAS No | 1953133-47-5 |
|---|---|
| Molecular Formula | C27H31F5N4O |
| Molecular Weight | 522.6 g/mol |
| Synonyms | 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Giredestrant is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation.
The listed CAS number is 1953133-47-5.
The listed molecular formula is C27H31F5N4O.
The listed molecular weight is 522.6 g/mol.
3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol.
The source lists RO-7197597 and GDC-9545.